• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates.

作者信息

Lian Yi, Voruganti Teja, Lu Jenny, Long Qi, Mamtani Ronac

机构信息

Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia.

Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia.

出版信息

JAMA Netw Open. 2025 Jul 1;8(7):e2519524. doi: 10.1001/jamanetworkopen.2025.19524.

DOI:10.1001/jamanetworkopen.2025.19524
PMID:40632539
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12242697/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2749/12242697/d1d72821cdbd/jamanetwopen-e2519524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2749/12242697/d1d72821cdbd/jamanetwopen-e2519524-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2749/12242697/d1d72821cdbd/jamanetwopen-e2519524-g001.jpg

相似文献

1
Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates.免疫检查点抑制剂（ICIs）和抗体药物偶联物应用前后尿路上皮癌的生存趋势
JAMA Netw Open. 2025 Jul 1;8(7):e2519524. doi: 10.1001/jamanetworkopen.2025.19524.
2
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.性别对免疫治疗和抗体药物偶联物在尿路上皮癌和肾癌患者中的肿瘤学结局的影响：系统评价和网络荟萃分析。
Eur Urol Oncol. 2024 Oct;7(5):1005-1014. doi: 10.1016/j.euo.2024.03.014. Epub 2024 Apr 21.
3
Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients With Metastatic Cancer.免疫检查点抑制剂与转移性癌症患者医疗保险覆盖范围导致的生存差异
JAMA Netw Open. 2025 Jul 1;8(7):e2519274. doi: 10.1001/jamanetworkopen.2025.19274.
4
Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.程序性细胞死亡配体 1 的表达作为一线免疫检查点抑制剂与化疗治疗转移性尿路上皮癌患者的预测性生物标志物：系统评价和荟萃分析。
Eur Urol Focus. 2022 Jan;8(1):152-159. doi: 10.1016/j.euf.2021.01.003. Epub 2021 Jan 27.
5
Impact of comorbidity on immune-related adverse events and survival in older cancer patients treated with immunotherapy.合并症对接受免疫治疗的老年癌症患者免疫相关不良事件和生存的影响。
Future Oncol. 2025 Jun;21(14):1787-1796. doi: 10.1080/14796694.2025.2502313. Epub 2025 May 27.
6
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.免疫检查点抑制剂在伴有副肿瘤综合征的实体瘤患者中的临床疗效和安全性。
J Immunother Cancer. 2024 Mar 5;12(3):e008724. doi: 10.1136/jitc-2023-008724.
7
Periodic Boosters of COVID-19 Vaccines Do Not Affect the Safety and Efficacy of Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: A Longitudinal Analysis of the Vax-On-Third Study.新冠疫苗的定期加强针不影响晚期非小细胞肺癌免疫检查点抑制剂的安全性和疗效：Vax-On-Third研究的纵向分析
Cancers (Basel). 2025 Jun 11;17(12):1948. doi: 10.3390/cancers17121948.
8
Response rate specific to bone metastasis of various cancers for immune checkpoint inhibitors: a systematic review.各种癌症骨转移的免疫检查点抑制剂的应答率：系统评价。
Eur J Orthop Surg Traumatol. 2024 Aug;34(6):2823-2833. doi: 10.1007/s00590-024-04018-1. Epub 2024 Jun 5.
9
Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.基于免疫检查点抑制剂治疗的晚期尿路上皮癌患者的体能状态对肿瘤学结局的影响：系统评价和荟萃分析。
Eur Urol Focus. 2023 Mar;9(2):264-274. doi: 10.1016/j.euf.2023.01.019. Epub 2023 Feb 9.
10
Selective Internal Radiation Therapy Combined with Immune Checkpoint Inhibitors in the Treatment of Hepatocellular Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.选择性内放射治疗联合免疫检查点抑制剂治疗肝细胞癌：一项系统评价和单臂荟萃分析
Dig Dis Sci. 2025 Jun 26. doi: 10.1007/s10620-025-09139-z.

本文引用的文献

1
Contemporary survival in metastatic bladder cancer patients: A population-based study.转移性膀胱癌患者的当代生存状况：一项基于人群的研究。
Int J Cancer. 2024 Nov 15;155(10):1762-1768. doi: 10.1002/ijc.35077. Epub 2024 Jul 3.
2
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.恩福妥单抗Vedotin 联合帕博利珠单抗治疗未经治疗的晚期尿路上皮癌。
N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117.
3
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.恩福妥单抗 Vedotin 治疗既往治疗的晚期尿路上皮癌。
N Engl J Med. 2021 Mar 25;384(12):1125-1135. doi: 10.1056/NEJMoa2035807. Epub 2021 Feb 12.
4
Development and Validation of a High-Quality Composite Real-World Mortality Endpoint.高质量综合真实世界死亡率终点的开发与验证
Health Serv Res. 2018 Dec;53(6):4460-4476. doi: 10.1111/1475-6773.12872. Epub 2018 May 14.
5
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.帕博利珠单抗作为晚期尿路上皮癌的二线治疗药物。
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.